Little-Used Drug Combination May Extend the Lives of Lung Transplant Patients
University of Maryland School of Medicine Data Analyses Identify Immunosuppression Regimen with Best Outcome
Lung transplantation can prolong the lives of patients with end-stage lung disease, but the median survival rate after a lung transplant is less than six years, which has improved only slightly in recent decades. To see what might help lung transplant recipients live longer, researchers at the University of Maryland School of Medicine (UMSOM) developed a novel epidemiological analysis of lung transplant data in the United States focused on regimens that prevent the body's immune system from attacking the transplanted lung. The study has identified a drug combination that appears to significantly extend patient survival.
To prevent chronic rejection, the most common cause of death after a lung transplant, patients must take immunosuppressive drugs for the rest of their lives. Immunosuppression, in turn, may predispose patients to infections and cancers, the second- and third-leading causes of post-lung transplant death. Few outcome studies have been done in the field of lung transplantation to determine what works best. Further, the U.S. Food and Drug Administration has not approved any immunosuppressive drugs or drug regimens specifically for use in patients with a lung transplant.
Using a database of over 9,000 lung transplant patients maintained by the United Network for Organ Sharing (UNOS), the researchers categorized patients by their immunosuppression regimen and compared survival rates. They singled out an immunosuppressive drug called sirolimus, in a class of drugs called cell cycle inhibitors, based on a few small, long-term studies that found dramatically improved survival, reduced incidence of chronic rejection, and improved lung function in lung transplant patients who took sirolimus.
The database study compared sirolimus outcomes with the most commonly used cell cycle inhibitor mycophenolate mofetil (MMF). "According to our study, sirolimus appears to offer a survival advantage of almost two years over MMF," said first author Marniker Wijesinha, PhD, a UMSOM post-doctoral fellow. "The survival improvement with sirolimus was driven by fewer deaths from the top three causes: chronic rejection, infections, and cancer."
Another immunosuppressive medication, tacrolimus, is currently used in the vast majority of lung transplant recipients and was common to all patients in the study. "The typical regimen consists of three drugs: tacrolimus, a cell cycle inhibitor, and steroids (prednisone)," said Dr. Wijesinha. "The variable in this study was the cell cycle inhibitor."
Sirolimus plus tacrolimus was associated with a better median survival than MMF plus tacrolimus (8.9 years vs 7.1 years).
The majority of patients in the database, nearly 5,800, were given MMF plus tacrolimus, a combination that has become the de facto standard immunosuppression after lung transplant. Sirolimus plus tacrolimus maintenance therapy was provided to slightly more than 200 patients.
One downside for sirolimus, though, is that it interferes with wound healing, a potentially life-threatening complication if the drug is administered in the initial days and weeks following transplant surgery. For this reason, prophylactic sirolimus maintenance therapy is typically not started until three to 12 months after surgery. The researchers accounted for this delayed initiation so sirolimus would not appear to yield a false survival advantage.
The study also considered induction therapy, an optional addition to maintenance therapy used in over half of transplant centers in the U.S. In induction therapy, patients are given a high dose of immunosuppression at the time of transplantation for a short duration – three to 14 days, with drugs such as basiliximab, daclizumab, alemtuzumab, or antithymocyte globulin.
The group that came out with the highest survival of all combinations was given sirolimus plus tacrolimus for maintenance therapy without induction therapy. These patients lived over three years longer on average than patients receiving MMF maintenance with induction therapy.
"This study illustrates the value of searching through large databases to discern patterns and practices that may not be immediately obvious, but can have a major impact on patient care," said UMSOM Dean E. Albert Reece, MD, PhD, MBA, University Executive Vice President for Medical Affairs and the John Z. and Akiko K. Bowers Distinguished Professor. "Further studies of patients undergoing lung transplantation are needed to confirm the findings associated with sirolimus, but this research is a great start."
"A particularly useful direction for a future study would be to investigate the optimal dosages of sirolimus and tacrolimus in lung transplant patients (which may vary according to patient characteristics)," said Dr. Wijesinha. "Our study, unfortunately, could not do this because there were no data on this."
Wijesinha M, Hirshon JM, Terrin M, Magder L, Brown C, Stafford K, Iacono A. "Survival Associated with Sirolimus Plus Tacrolimus Maintenance Without Induction Therapy Compared With Standard Immunosuppression After Lung Transplant." JAMA Network Open. 2019;2(8):e191027. doi:10.1001/jamanetworkopen.2019.10297
About the University of Maryland School of Medicine
Now in its third century, the University of Maryland School of Medicine was chartered in 1807 as the first public medical school in the United States. It continues today as one of the fastest growing, top-tier biomedical research enterprises in the world -- with 43 academic departments, centers, institutes, and programs; and a faculty of more than 3,000 physicians, scientists, and allied health professionals, including members of the National Academy of Medicine and the National Academy of Sciences, and a distinguished recipient of the Albert E. Lasker Award in Medical Research. With an operating budget of more than $1 billion, the School of Medicine works closely in partnership with the University of Maryland Medical Center and Medical System to provide research-intensive, academic and clinically based care for more than 1.2 million patients each year. The School has over 2,500 students, residents, and fellows, and more than $530 million in extramural funding, with most of its academic departments highly ranked among all medical schools in the nation in research funding. As one of the seven professional schools that make up the University of Maryland, Baltimore campus, the School of Medicine has a total workforce of nearly 7,000 individuals. The combined School and Medical System ("University of Maryland Medicine") has an annual budget of nearly $6 billion and an economic impact more than $15 billion on the state and local community. The School of Medicine faculty, which ranks as the 8th highest among public medical schools in research productivity, is an innovator in translational medicine, with 600 active patents and 24 start-up companies. The School works locally, nationally, and globally, with research and treatment facilities in 36 countries around the world. Visit medschool.umaryland.edu.
About the University of Maryland Medical Center
The University of Maryland Medical Center (UMMC) is comprised of two hospitals in Baltimore: an 841-bed teaching hospital Downtown – the flagship institution of the 14-hospital University of Maryland Medical System (UMMS) – and a 177-bed teaching hospital, UMMC Midtown Campus. UMMC is a national and regional referral center for trauma, cancer care, neuroservices, cardiac care, diabetes and endocrinology, women's and children's health. All physicians on staff at the Downtown flagship hospital are faculty physicians of the University of Maryland School of Medicine. At UMMC Midtown Campus, faculty physicians work alongside community physicians to provide patients with the highest quality care. UMMC Midtown Campus was founded in 1881 and is located one mile away from the Downtown Campus. For more information, visit umm.edu.